ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 7, 2021

8:30AM-10:30AM: Abstract Number: 0735

Walking Ability 12 Months After Total Knee Arthroplasty for Osteoarthritis – Gap Between Expectations and Reality: The BEST Knee Cohort Study

Osteoarthritis – Clinical Poster II (0723–0738)

8:30AM-10:30AM: Abstract Number: 0763

What Does the Patient Well-Being Vas Tell Us When the Physician Global Assessmentscore Is Zero? Analysis of a Large Multinational Dataset

Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)

8:30AM-10:30AM: Abstract Number: 0842

What Is the Success Rate in Clinical Trials of Discontinuation Glucocorticoids After Their Use as Bridging Therapy – a Systematic Literature Review

RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)

8:30AM-10:30AM: Abstract Number: 0664

Which Attributes Are the Most and Least Important to Patients When Considering Gout Flare Burden over Time? A Best-worst Scaling Choice Study

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)

8:30AM-10:30AM: Abstract Number: 0927

Whole Blood Transcriptional Changes Following Treatment with Filgotinib in Patients with Ankylosing Spondylitis

Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)

8:30AM-10:30AM: Abstract Number: 0575

World Mortality of Spondyloarthritis and Inflammatory Bowel Diseases in 2015 and Its Evolution Between 2001 and 2015

Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)

9:00AM-9:15AM: Abstract Number: 0944

A Characterization of the Gut and Cutaneous Microbiome of Monozygotic Twins Discordant for Psoriatic Disease

Abstracts: Spondyloarthritis Including PsA – Basic Science (0944–0947)

9:00AM-9:15AM: Abstract Number: 0948

Immunometabolism of Neutrophils in Antiphospholipid Syndrome (APS)

Abstracts: Antiphospholipid Syndrome (0948–0951)

9:00AM-9:15AM: Abstract Number: 0952

Outcomes of COVID-19 Infection in Patients with Primary Systemic Vasculitis and Polymyalgia Rheumatica: Results from the COVID-19 Global Rheumatology Alliance Physician Registry

Abstracts: Vasculitis – ANCA-Associated (0952–0955)

9:00AM-9:15AM: Abstract Number: 0940

Overactivation of the Kinase IKK2 Causes a Hand Osteoarthritis-Like Phenotype in Mice

Abstracts: Osteoarthritis & Joint Biology – Basic Science (0940–0943)

9:15AM-9:30AM: Abstract Number: 0945

A Single-cell Atlas of Human Synovial Endothelial Cells in Inflammatory Arthritis

Abstracts: Spondyloarthritis Including PsA – Basic Science (0944–0947)

9:15AM-9:30AM: Abstract Number: 0953

An International Delphi Exercise to Identify Items of Importance for Measuring Response to Treatment for ANCA-associated Vasculitis

Abstracts: Vasculitis – ANCA-Associated (0952–0955)

9:15AM-9:30AM: Abstract Number: 0941

Lorecivivint (SM04690), an Intra-articular, Small-Molecule CLK/DYRK Inhibitor That Modulates the Wnt Pathway, Provided Cartilage-Protective Effects in an Animal Model of Post-traumatic OA

Abstracts: Osteoarthritis & Joint Biology – Basic Science (0940–0943)

9:15AM-9:30AM: Abstract Number: 0949

Single-Cell RNA Sequencing of APS Skin Reveals Endothelial Pathology and Cellular Interactions

Abstracts: Antiphospholipid Syndrome (0948–0951)

9:30AM-9:45AM: Abstract Number: 0946

Distinct Lipidomic Signatures in Synovium and Synovial Fluid of Patients with Rheumatoid Arthritis versus Psoriatic Arthritis

Abstracts: Spondyloarthritis Including PsA – Basic Science (0944–0947)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].